Bioluminescence imaging for tumor progression monitoring

Explicyte is providing invaluable orthotopic tumor-bearing models which permit accurate expression of the tumor nature in terms of growth rate, morphology and metastasis and thus mimic the disease progression thereby allowing an accurate assessment of treatments response. Since these are based on the implantation of tumor cells engineered to stably express the firefly luciferase, bioluminescent signal is emitted from the cells following luciferase substrate administration, thereby making bioluminescence imaging a powerful means to monitor and quantify tumor growth progression for the evaluation of treatments efficacy in those models.
 

Key advantages of bioluminescence imaging

  • Quantitative means to track tumor burden in orthotopic and disseminated tumor models.
  • Adapted, along with fluorescence imaging (2D and 3D), for e.g .in vivo targeting of therapeutics and tissue bio-distribution, and to monitor where and/or when some processes take place.

Illustrative data

Orthotopic breast 4T1-Luc2 tumor-bearing model
Bioluminescence imaging of orthotopic 4T1-Luc2 tumor-bearing model.
 

Bioluminescence imaging of orthotopic 4T1-Luc2 tumor-bearing model.  

Orthotopic glioma GL261-Luc2 tumor-bearing model

Mice were implanted with GL261-Luc2 glioma cells and then TMZ-treated. Representative images and quantitative data of bioluminescence imaging at days 7, 14, and 21 post tumor cell implantation.

Mice were implanted with GL261-Luc2 glioma cells and then TMZ-treated. Representative images ...